Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study.
Alzheimer’s disease
Cognitive decline
Cognitive domains performance
Neurodegenerative diseases
Neurofilament proteins
Neuroimaging
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
23
06
2024
accepted:
02
10
2024
medline:
20
10
2024
pubmed:
20
10
2024
entrez:
19
10
2024
Statut:
epublish
Résumé
Analysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well as longitudinal cognitive decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice. Despite its potential prognostic significance, the role of plasma NfL in daily clinical practice with unselected patients suffering from cognitive impairment remains largely unexplored. This retrospective, cross-sectional and longitudinal monocentric study enrolled 320 patients with Alzheimer's disease ([AD], n = 158), dementia with Lewy body ([DLB], n = 30), frontotemporal dementia ([FTD], n = 32), non-neurodegenerative diseases ([NND], n = 59) or subjective cognitive decline ([SCD], n = 41). Plasma NfL levels were measured at baseline on the Simoa platform. AD, DLB, and FTD patients were also analyzed altogether as a 'degenerative conditions' subgroup, whereas SCD and NND were grouped as a 'non-degenerative conditions' subgroup. We assessed the relationship between plasma NfL levels and cross-sectional cognitive performance, including global cognition and six specific cognitive domains. A subset of 239 patients had follow-up mini-mental state examinations (MMSE) up to 60 months. Models were adjusted on age, education level, glomerular filtration rate and body mass index. In 320 patients, baseline plasma NfL levels were negatively associated with global cognition (β=-1.28 (-1.81 ; -0.75) P < 0.001), memory (β=-1.48 (-2.38 ; -0.59), P = 0.001), language (β=-1.72(-2.49 ; -0.95) P < 0.001), praxis (β=-2.02 (-2.91 ; -1.13) P < 0.001) and executive functions (β=-0.81, P < 0.001). Across diagnosis, plasma NfL levels were negatively associated with cross-sectional global cognition in all but the SCD subgroup, specifically with executive functions and memory in AD (respectively β=-0.71(-1.21 ; -0.211), P = 0.005 and β=-1.29 (-2.17 ; -0.42), P = 0.004), and with attention in LBD (β=-0.81(-1.16 ; -0.002), P = 0.03). Linear mixed-effects models showed that plasma NfL predicted MMSE decline in the global population (β In our clinical cohort, plasma NfL was associated with faster cognitive decline in neurodegenerative dementia, which corroborates data obtained in research cohorts. Yet, plasma NfL was not predictive of accelerated cognitive decline in individuals without neurodegeneration, suggesting its use as a neurodegeneration-specific predictive biomarker.
Sections du résumé
BACKGROUND
BACKGROUND
Analysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well as longitudinal cognitive decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice. Despite its potential prognostic significance, the role of plasma NfL in daily clinical practice with unselected patients suffering from cognitive impairment remains largely unexplored.
METHODS
METHODS
This retrospective, cross-sectional and longitudinal monocentric study enrolled 320 patients with Alzheimer's disease ([AD], n = 158), dementia with Lewy body ([DLB], n = 30), frontotemporal dementia ([FTD], n = 32), non-neurodegenerative diseases ([NND], n = 59) or subjective cognitive decline ([SCD], n = 41). Plasma NfL levels were measured at baseline on the Simoa platform. AD, DLB, and FTD patients were also analyzed altogether as a 'degenerative conditions' subgroup, whereas SCD and NND were grouped as a 'non-degenerative conditions' subgroup. We assessed the relationship between plasma NfL levels and cross-sectional cognitive performance, including global cognition and six specific cognitive domains. A subset of 239 patients had follow-up mini-mental state examinations (MMSE) up to 60 months. Models were adjusted on age, education level, glomerular filtration rate and body mass index.
RESULTS
RESULTS
In 320 patients, baseline plasma NfL levels were negatively associated with global cognition (β=-1.28 (-1.81 ; -0.75) P < 0.001), memory (β=-1.48 (-2.38 ; -0.59), P = 0.001), language (β=-1.72(-2.49 ; -0.95) P < 0.001), praxis (β=-2.02 (-2.91 ; -1.13) P < 0.001) and executive functions (β=-0.81, P < 0.001). Across diagnosis, plasma NfL levels were negatively associated with cross-sectional global cognition in all but the SCD subgroup, specifically with executive functions and memory in AD (respectively β=-0.71(-1.21 ; -0.211), P = 0.005 and β=-1.29 (-2.17 ; -0.42), P = 0.004), and with attention in LBD (β=-0.81(-1.16 ; -0.002), P = 0.03). Linear mixed-effects models showed that plasma NfL predicted MMSE decline in the global population (β
CONCLUSION
CONCLUSIONS
In our clinical cohort, plasma NfL was associated with faster cognitive decline in neurodegenerative dementia, which corroborates data obtained in research cohorts. Yet, plasma NfL was not predictive of accelerated cognitive decline in individuals without neurodegeneration, suggesting its use as a neurodegeneration-specific predictive biomarker.
Identifiants
pubmed: 39427171
doi: 10.1186/s13195-024-01593-7
pii: 10.1186/s13195-024-01593-7
doi:
Substances chimiques
Neurofilament Proteins
0
neurofilament protein L
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
231Subventions
Organisme : Swedish research council
ID : 2023-00356
Organisme : Swedish research council
ID : 2022-0732
Organisme : European Union Horizon Europe research and innovation program
ID : 101053962
Organisme : Alzheimer's Drug Discovery Foundation
ID : 201809
Organisme : Horizon 2020
ID : 860197
Organisme : European Union joint program
ID : JPND2021-00694
Organisme : Swedish Alzheimer foundation
ID : AF-930351
Organisme : Hjärnfonden
ID : ALZ2022-00066
Organisme : European union joint programfor neurodegenerative disorders
ID : JPND2019-466-236
Organisme : Alzheimer 's association 2022-2025 Grant
ID : SG-23-1038904
Informations de copyright
© 2024. The Author(s).
Références
Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med CCLM [Internet]. 2016 [cited 2021 Mar 24];54. https://www.degruyter.com/document/doi/ https://doi.org/10.1515/cclm-2015-1195/html
Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels in Alzheimer’s disease. Neurosci Lett. 2017;650:60–4.
pubmed: 28428015
doi: 10.1016/j.neulet.2017.04.027
Mattsson N, Andreasson U, Zetterberg H, Blennow K. For the Alzheimer’s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer Disease. JAMA Neurol. 2017;74:557.
pubmed: 28346578
pmcid: 5822204
doi: 10.1001/jamaneurol.2016.6117
Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25:277–83.
pubmed: 30664784
pmcid: 6367005
doi: 10.1038/s41591-018-0304-3
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of Disease Progression in Mouse models and in neurodegenerative diseases. Neuron. 2016;91:56–66.
pubmed: 27292537
doi: 10.1016/j.neuron.2016.05.018
Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther. 2018;10:71.
pubmed: 30055655
pmcid: 6064615
doi: 10.1186/s13195-018-0404-9
Götze K, Vrillon A, Bouaziz-Amar E, Mouton-Liger F, Hugon J, Martinet M, et al. Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis. 2023;176:105937.
pubmed: 36462720
doi: 10.1016/j.nbd.2022.105937
Vrillon A, Ashton NJ, Karikari TK, Götze K, Cognat E, Dumurgier J et al. Comparison of CSF and plasma NfL and pNfH for Alzheimer’s disease diagnosis: a memory clinic study. J Neurol. 2023.
Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.
pubmed: 34099648
pmcid: 8185001
doi: 10.1038/s41467-021-23620-z
Benussi A, Karikari TK, Ashton N, Gazzina S, Premi E, Benussi L, et al. Diagnostic and prognostic value of serum NfL and p-Tau
pubmed: 32611664
doi: 10.1136/jnnp-2020-323487
Illán-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, et al. Plasma tau and neurofilament light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology. 2021;96:e671–83.
pubmed: 33199433
pmcid: 7884995
doi: 10.1212/WNL.0000000000011226
Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93:651–8.
pubmed: 35078917
doi: 10.1136/jnnp-2021-327788
Davy V, Dumurgier J, Fayosse A, Paquet C, Cognat E. Neurofilaments as emerging biomarkers of Neuroaxonal damage to differentiate behavioral Frontotemporal Dementia from Primary Psychiatric disorders: a systematic review. Diagnostics. 2021;11:754.
pubmed: 33922390
pmcid: 8146697
doi: 10.3390/diagnostics11050754
Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer’s Disease. Neurobiol Aging. 2020;94:60–70.
pubmed: 32585491
pmcid: 7484086
doi: 10.1016/j.neurobiolaging.2020.05.011
Bangen KJ, Thomas KR, Weigand AJ, Edmonds EC, Clark AL, Solders S, et al. Elevated plasma neurofilament light predicts a faster rate of Cognitive decline over 5 years in participants with objectively-defined subtle cognitive difficulties and MCI. Alzheimers Dement J Alzheimers Assoc. 2021;17:1756–62.
doi: 10.1002/alz.12324
Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light. Neurology. 2019;93:e252–60.
pubmed: 31182505
pmcid: 6656645
doi: 10.1212/WNL.0000000000007767
Sapkota S, Erickson K, Harvey D, Tomaszewski-Farias SE, Olichney JM, Johnson DK, et al. Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: mediation with hippocampal volume. Alzheimers Dement Diagn Assess Dis Monit. 2022;14:e12349.
De Meyer S, Blujdea ER, Schaeverbeke J, Reinartz M, Luckett ES, Adamczuk K, et al. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes. Brain J Neurol. 2024;147:936–48.
doi: 10.1093/brain/awad330
Dark HE, An Y, Duggan MR, Joynes C, Davatzikos C, Erus G, et al. Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Alzheimers Res Ther. 2024;16:94.
pubmed: 38689358
pmcid: 11059745
doi: 10.1186/s13195-024-01459-y
Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;alz.13859.
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.
pubmed: 29653606
doi: 10.1016/j.jalz.2018.02.018
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7:263–9.
doi: 10.1016/j.jalz.2011.03.005
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.
pubmed: 28592453
pmcid: 5496518
doi: 10.1212/WNL.0000000000004058
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain J Neurol. 2011;134:2456–77.
doi: 10.1093/brain/awr179
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.
pubmed: 21325651
pmcid: 3059138
doi: 10.1212/WNL.0b013e31821103e6
Gendron TF, Badi MK, Heckman MG, Jansen-West KR, Vilanilam GK, Johnson PW, et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci Transl Med. 2020;12:eaay1913.
pubmed: 33177179
pmcid: 9534269
doi: 10.1126/scitranslmed.aay1913
Akel S, Asztely F, Banote RK, Axelsson M, Zetterberg H, Zelano J. Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: high plasma levels are rare but related to seizures. Epilepsia. 2023;64:2690–700.
pubmed: 37469165
doi: 10.1111/epi.17713
Barbeau E, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, et al. Evaluation of visual recognition memory in MCI patients. Neurology. 2004;62:1317–22.
pubmed: 15111668
doi: 10.1212/01.WNL.0000120548.24298.DB
Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13–36.
doi: 10.1080/87565648709540361
Godefroy O, Grefex. Fonctions exécutives et pathologies neurologiques et psychiatriques, évaluation en pratique clinique [Internet]. deboeck. 2012 [cited 2023 Oct 24]. https://www.deboecksuperieur.com/ouvrage/9782353270378-fonctions-executives-et-pathologies-neurologiques-et-psychiatriques
Deloche G, Hannequin D. Test De dénomination Orale d’images: DO 80. Paris, France: ECPA, Les éditions du Centre de psychologie appliquée; 1997.
Merck C, Charnallet A, Auriacombe S, Belliard S, Hahn-Barma V, Kremin H, et al. La Batterie d’évaluation des connaissances sémantiques du GRECO (BECSGRECO): validation et données normatives. Rev Neuropsychol. 2011;3:235–55.
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55:1621–6.
pubmed: 11113214
doi: 10.1212/WNL.55.11.1621
Osterrieth PA. Le test de copie d’une figure complexe; contribution à l’étude de la perception et de la mémoire. [Test of copying a complex figure; contribution to the study of perception and memory]. Arch Psychol. 1944;30:206–356.
Wechsler D. Wechsler Adult Intelligence Scale–Fourth Edition. Pearson. 2008.
Mahieux-Laurent F, Fabre C, Galbrun E, Dubrulle A, Moroni C. Groupe de réflexion sur les praxies du CMRR ile-de-france Sud. [Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients]. Rev Neurol (Paris). 2009;165:560–7.
pubmed: 19150097
doi: 10.1016/j.neurol.2008.11.016
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging [Internet]. [cited 2023 Oct 2]. https://www.ajronline.org/doi/epdf/ https://doi.org/10.2214/ajr.149.2.351
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967–72.
pubmed: 1431963
pmcid: 1015202
doi: 10.1136/jnnp.55.10.967
Schubert CR, Paulsen AJ, Pinto AA, Merten N, Cruickshanks KJ. Effect of long-term storage on the reliability of blood biomarkers for Alzheimer’s Disease and Neurodegeneration. J Alzheimers Dis JAD. 2022;85:1021–9.
pubmed: 34924380
doi: 10.3233/JAD-215096
Poli M, Benerini Gatta L, Dominici R, Lovati C, Mariani C, Albertini A, et al. Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography - PubMed. Clin Chem Lab Med CCLM. 2005;43:512–8.
pubmed: 15899673
de Crom TOE, Ghanbari M, Voortman T, Ikram MA. Body composition and plasma total-tau, neurofilament light chain, and amyloid-β: a population-based study. Alzheimers Dement Amst Neth. 2024;16:e12519.
doi: 10.1002/dad2.12519
Manouchehrinia A, Piehl F, Hillert J, Kuhle J, Alfredsson L, Olsson T, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7:139–43.
pubmed: 31893563
pmcid: 6952306
doi: 10.1002/acn3.50972
Wu J, Xiao Z, Wang M, Wu W, Ma X, Liang X et al. The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study. Alzheimers Res Ther [Internet]. 2024 [cited 2024 May 11];16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10860286/
Régy M, Dugravot A, Sabia S, Bouaziz-Amar E, Paquet C, Hanseeuw B, et al. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders. Alzheimers Res Ther. 2023;15:77.
pubmed: 37038213
pmcid: 10088112
doi: 10.1186/s13195-023-01220-x
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78:1–13.
pmcid: 8524356
doi: 10.1001/jamaneurol.2021.3671
Marks JD, Syrjanen JA, Graff-Radford J, Petersen RC, Machulda MM, Campbell MR, et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther. 2021;13:199.
pubmed: 34906229
pmcid: 8672619
doi: 10.1186/s13195-021-00944-y
Darmanthé N, Tabatabaei-Jafari H, Cherbuin N, Alzheimer’s Disease Neuroimaging Initiative. Combination of plasma neurofilament light chain and mini-mental state examination score predicts progression from mild cognitive impairment to Alzheimer’s disease within 5 years. J Alzheimers Dis JAD. 2021;82:951–64.
pubmed: 34120902
doi: 10.3233/JAD-210092